Johns Hopkins Medicine: One Versus Three: Clinical Trial Shows Daily Meds for a Month Comparable to Once Weekly for Three Months to Treat Latent TB

10 February 2026

Johns Hopkins Medicine press release

One of the current stalwarts in the fight against TB has been treatment of its latent form with a combination of two drugs, isoniazid and rifapentine, in a three-month, weekly regimen (12 doses) known as 3HP (H for isoniazid and P for rifapentine). A second regimen, 1HP, requires the drugs to be taken daily, but just for one month (30 doses). It has been recommended for people living with both TB and HIV, and for those over age 13 who have been in contact with people infected with TB.

What has not been known previously is whether 1HP also would be safe and effective for patients with latent TB infection and without HIV, for whom current practice would advise a 3HP regimen.

In a study published in PLOS Medicine, researchers demonstrated that the 1HP regimen is safe, encourages patients to complete the course of therapy, and has a high rate of treatment success comparable to that seen with 3HP.

Read the full press release here.

Source: Johns Hopkins Medicine